Inflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy
Customize your policy alerts
Sign up for Aspirus Arise POLIcY: Inflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy alerts
Get alerted when POLIcY: Inflammatory Conditions Tocilizumab Intravenous Products Utilization Management Medical Policy changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization, coverage criteria, dosing, and specialty prescriber requirements for intravenous tocilizumab products (Actemra, Tofidence and listed biosimilars) for Aspirus Medicare plans.
Cytokine Release Syndrome Associated with Bispecific Antibodies was added as a condition of approval.
Step therapy updated to require documentation of clinical need for non-preferred product over preferred biosimilars.
Added age requirements for initial approvals for multiple indications (e.g., Giant Cell Arteritis, RA, SJIA, Castleman disease, immunotherapy-related toxicities, polymyalgia rheumatica, Still's disease).
Acute treatment of COVID-19 in hospitalized patients is not addressed in this policy.
Coverage Criteria and Indications
CRS (CAR T-cell therapy)
Covered when ALL of the following are met
Approve for 1 week (adequate to receive up to four doses). Dosing: if patient <30 kg, up to 12 mg/kg (maximum 800 mg per dose); if patient ≥30 kg, up to 8 mg/kg (maximum 800 mg per dose). Approve up to four doses if there will be an interval of at least 8 hours between doses.
Giant Cell Arteritis
Covered when ONE of the following is met
Initial: approve for 6 months. Continuation: approve for 1 year if established ≥6 months. Dosing: approve up to 6 mg/kg (maximum 600 mg) with interval of at least 4 weeks between doses.
Polyarticular JIA
Covered when ONE of the following is met
Initial: approve for 6 months. Continuation: approve for 1 year if established ≥6 months. Dosing: if <30 kg, approve up to 10 mg/kg (maximum 800 mg) with interval at least 4 weeks between doses.
Rheumatoid Arthritis
Covered when ONE of the following is met
Dosing: approve up to 8 mg/kg (maximum 800 mg) with interval of at least 4 weeks between doses. Initial approvals and continuation approvals as specified.
Systemic JIA / Still's disease
Covered when ONE of the following is met
Initial: approve for 6 months. Continuation: approve for 1 year if established ≥6 months. Dosing: if <30 kg, up to 12 mg/kg per dose; if ≥30 kg, up to 8 mg/kg per dose. Interval between doses at least 1–2 weeks depending on age/indication per prescribing criteria.
Castleman Disease
Covered when ALL of the following are met
Initial approval: 6 months if all initial criteria met. Continuation: approve for 1 year if established on therapy ≥6 months and meets at least ONE of: (a) beneficial clinical response by at least one objective measure from baseline (e.g., normalization/improvement of CRP, ESR, fibrinogen, albumin, hemoglobin, increased BMI, or reduction in lymphadenopathy); OR (b) improvement in at least one symptom such as resolution of constitutional symptoms or improved physical function.
Continuation Therapy (example structure from pediatric indication)
Covered when ALL/OR combinations described are met for continuation:
A patient who received <6 months of therapy or is restarting therapy is reviewed under Initial Therapy criteria.
Castleman Disease — Initial and Continuation Criteria
Approve for specified duration if one of the following applies:
Initial approval duration: 6 months. Continuation approval: 1 year if established ≥6 months and response criteria met.
Cytokine Release Syndrome Associated with Bispecific Antibodies
Covered when the following are met:
Approve for 1 week to allow up to four doses. Dosing: if patient <30 kg, up to 12 mg/kg (maximum 800 mg per dose); if patient ≥30 kg, up to 8 mg/kg (maximum 800 mg per dose). There must be an interval of at least 8 hours between doses.
Graft-Versus-Host Disease and Immunotherapy-Related Toxicities
Covered when indication-specific criteria met:
Initial approval: 1 month. If currently receiving tocilizumab and criteria met, approve continuation for 3 months. Examples of systemic medications include corticosteroids, antithymocyte globulin, cyclosporine, tacrolimus, mycophenolate, ruxolitinib, basiliximab, etanercept, infliximab, sirolimus, pentostatin, vedolizumab.
Initial approval: 6 months. Continuation approval: 1 year if established ≥6 months and response criteria met. Specialist prescribing for continuation may include rheumatology, hepatology, gastroenterology, pulmonology, or oncology.
Polymyalgia Rheumatica and Adult-Onset Still's Disease
Covered when indication-specific criteria met:
Initial approval when criteria met; continuation approval for 1 year if established ≥6 months and response criteria met. Dosing: approve up to 6 mg/kg (maximum 600 mg) with interval of at least 4 weeks between doses.
Initial approval: 6 months. Continuation approval: 1 year if established ≥6 months. Dosing: approve up to 8 mg/kg per dose with interval of at least 2 weeks between doses.
The acute treatment of hospitalized patients with COVID-19 is not addressed in this policy. Prior authorization guidance and recommended indications in this document do not apply to the inpatient acute management of COVID-19.
Use of tocilizumab for COVID-19 is generally not recommended in this policy except where explicitly described. The policy notes that tocilizumab IV is indicated only for hospitalized adults with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive ventilation, or ECMO; dosing for that indication is a single 8 mg/kg infusion (maximum 800 mg) with an optional second dose ≥8 hours later if clinically indicated.
Concurrent administration of tocilizumab with another biologic agent or with a targeted synthetic oral small molecule drug for an inflammatory condition is not recommended. Combination biologic or targeted synthetic therapy is discouraged due to increased risk of adverse events and lack of supportive controlled data; this restriction does not apply to concomitant use of conventional synthetic DMARDs such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine.
Coverage of tocilizumab for Crohn's disease is not recommended based on limited pilot study data. The policy cites a 12-week pilot trial that did not provide sufficient evidence of durable benefit, and states further studies are needed before coverage is supported.
The list of indications and examples in the appendix is not exhaustive. Oncology indications and rare inflammatory conditions are not listed here; refer to the product prescribing information and emerging literature for other potential uses.
Requests for a non-preferred tocilizumab product will be subject to step therapy rules. A non-preferred product may be approved only if the patient is not a new start to the non-preferred product within the prior 365 days, has a documented allergy or intolerance to all preferred products, has therapeutic failure of preferred products after an adequate trial, or has a diagnosis covered only by the non-preferred product. For patients new to therapy, chart documentation is required to justify use of a non-preferred product over the preferred biosimilar.
Requests for indications or clinical circumstances not listed in the Recommended Authorization Criteria are not recommended for approval and will be considered not medically necessary until new published data are available. The policy specifically identifies COVID-19 outside the described hospitalized setting and other off-criteria uses as common denial triggers.
Coding, Products, and Dosing Information
| CRS (CAR T-cell therapy) | Cytokine Release Syndrome associated with Chimeric Antigen Receptor (CAR) T-Cell Therapy — approve for 1 week (adequate to receive up to four doses); weight-based dosing: <30 kg up to 12 mg/kg (max 800 mg) or ≥30 kg up to 8 mg/kg (max 800 mg); interval ≥8 hours between doses. |
| Giant Cell Arteritis | Giant Cell Arteritis — patient ≥18 years; initial therapy approve 6 months with trial of or contraindication to systemic corticosteroid and prescribed by/with rheumatologist; continuation approvals as specified. |
| Polyarticular Juvenile Idiopathic Arthritis (PJIA) | Polyarticular JIA — patient ≥2 years; initial and continuation criteria apply; pediatric dosing and limits specified in policy. |
| Rheumatoid Arthritis (RA) | Rheumatoid arthritis — patient ≥18 years; requires trial of conventional DMARDs or prior biologic as specified; dosing up to 8 mg/kg (max 800 mg). |
| Systemic Juvenile Idiopathic Arthritis (SJIA) / Still's disease | Systemic JIA/Still's disease — patient ≥2 years (or adult-onset for AOSD); dosing: <30 kg up to 12 mg/kg per dose or ≥30 kg up to 8 mg/kg per dose; interval and approval durations as specified. |
| Castleman Disease | Castleman disease — other use with supportive evidence; patient ≥18 years, HIV- and HHV-8-negative, relapsed/refractory disease, prescribed by/with oncologist or hematologist; initial and continuation criteria and objective response measures apply. |
| Tyenne (biosimilar) | Preferred biosimilar product added as preferred for patients new to therapy (preferred before Actemra and Tofidence). |
| Actemra | Actemra — tocilizumab intravenous infusion product (non-preferred in step therapy). |
| Tofidence | Tofidence — tocilizumab intravenous product (non-preferred biosimilar). |
Prior Authorization, Step Therapy, and Provider Requirements
Prior authorization required
Prior authorization is required for medical benefit coverage of tocilizumab intravenous products; approvals are time-limited and contingent on meeting the indication-specific criteria and dosing. Initial approval requires the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated.
Indication- and duration-based prior authorization
Authorization is granted only when the request meets the indication-specific initial or continuation criteria (examples: age thresholds, specialist prescribing/consultation, prior therapy or established duration on therapy, objective measures of response) and dosing limits; approvals are issued for specified durations (e.g., 1 week, 1 month, 6 months, 1 year) depending on the indication.
Appendix reference for prior authorization reviews
Use the policy appendix to identify agent names, formulations, mechanisms of action, and example inflammatory indications when conducting prior authorization reviews; the appendix is descriptive and does not define single-code authorization rules.
Preferred product step therapy requirements
Requests for non-preferred products (Actemra, Tofidence) must meet the preferred-product step therapy requirements before authorization will be granted unless a listed exception applies (e.g., not a new start, documented allergy/intolerance, therapeutic failure of preferred products, or diagnosis included only for the non-preferred product).
- Preferred product: Tyenne; Non-preferred: Actemra, Tofidence
- Exceptions include: not a new start within prior 365 days; documented allergy/intolerance to preferred products; therapeutic failure of preferred products; diagnosis covered only by non-preferred product
Preferred biosimilar step
A preferred biosimilar (Tyenne) is designated as the preferred product for patients new to therapy; use of Actemra or Tofidence for patients new to therapy requires demonstration of clinical need and fulfillment of step therapy exceptions.
- Tyenne is the preferred product for patients new to therapy
- Policy history documents addition of preferred biosimilar step effective 1/1/2025
No step therapy algorithms specified
No step therapy algorithms or sequencing requirements (beyond the preferred-product exceptions) are specified in the appendix text provided.
Required documentation
Document indication-specific criteria, prior therapy trials as required by the indication (for example corticosteroids or conventional DMARDs), and that the drug is prescribed by or in consultation with a specialist (rheumatologist, oncologist/hematologist, or other condition specialist as specified).
- Examples: trial of systemic corticosteroid for polymyalgia rheumatica; trial of one conventional DMARD for rheumatoid arthritis; specialist prescribing/consultation requirement
Step therapy documentation
For requests to use a non-preferred product in place of the preferred biosimilar (patients new to therapy), include chart note documentation supporting the clinical need for the non-preferred product (e.g., allergy/intolerance, therapeutic failure, or diagnosis-specific rationale).
- Chart notes must support clinical need for non-preferred product over Tyenne for patients new to therapy
Refer to prescribing information
Refer to each agent's prescribing information for FDA‑approved indications when confirming indication-specific coverage and dosing.
Authorization and step therapy denial risk
Requests may be denied if prior authorization is not obtained or if step therapy requirements are not met (for example, use of a non-preferred product without meeting the step therapy exceptions or required documentation).
Common denial triggers
Common triggers for denial include requests for tocilizumab IV for COVID-19 outside the limited hospitalized adults population described in the policy and requests for concurrent use with another biologic or a targeted synthetic oral small molecule for an inflammatory condition.
- COVID-19: policy does not recommend use except as explicitly described (hospitalized adults meeting specific criteria)
- Concurrent use with another biologic or targeted synthetic oral small molecule for an inflammatory condition is not recommended and may be denied
Appendix descriptive only
The appendix content is descriptive and reference-only; no additional authorization restrictions are specified in the appendix chunks reviewed.
Background and Scope
Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor with multiple FDA-approved inflammatory and immune-related indications, including cytokine release syndrome (CRS) associated with CAR T-cell therapy, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis / Still's disease, and rheumatoid arthritis. The agent is also listed for several other uses with supportive evidence (e.g., Castleman disease, graft-versus-host disease, immunotherapy-related toxicities, polymyalgia rheumatica) in the policy appendix. Because of the specialized evaluation and monitoring required, initial approvals generally require prescription by or consultation with a specialist in the condition being treated, and prior authorization is required for medical benefit coverage.
Definitions and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.